

MAINE STATE LEGISLATURE

The following document is provided by the
LAW AND LEGISLATIVE DIGITAL LIBRARY
at the Maine State Law and Legislative Reference Library
<http://legislature.maine.gov/lawlib>



Reproduced from electronic originals
(may include minor formatting differences from printed original)



126th MAINE LEGISLATURE

FIRST REGULAR SESSION-2013

Legislative Document

No. 338

H.P. 243

House of Representatives, February 12, 2013

**Resolve, Directing the Department of Health and Human Services
To Amend Its Rules Governing the Use of Certain Antipsychotic
Drugs by Children Enrolled in MaineCare**

Reference to the Committee on Health and Human Services suggested and ordered printed.

Millicent M. MacFarland
MILLICENT M. MacFARLAND
Clerk

Presented by Representative MALABY of Hancock.
Cosponsored by Senator LACHOWICZ of Kennebec and
Representatives: CASSIDY of Lubec, DUNPHY of Embden, FITZPATRICK of Houlton,
HAYES of Buckfield, McELWEE of Caribou, SANDERSON of Chelsea, SIROCKI of
Scarborough, WELSH of Rockport.

1 **Sec. 1. Rules. Resolved:** That the Department of Health and Human Services
2 shall amend its rules pertaining to the use of atypical antipsychotic medications by a child
3 under 17 years of age enrolled in MaineCare to require that the prescriber of atypical
4 antipsychotic medication beyond the recommended period provide documented
5 justification as to why the child should continue taking the medication and to require that
6 the prescriber perform a timely assessment and ongoing monitoring of metabolic and
7 neurologic variables of the child in accordance with the American Academy of Child and
8 Adolescent Psychiatry's Practice Parameter for the Use of Atypical Antipsychotic
9 Medications in Children and Adolescents.

10

SUMMARY

11 This resolve directs the Department of Health and Human Services to amend its rules
12 governing the use of atypical antipsychotic drugs by children enrolled in MaineCare to
13 require that the prescriber of a drug beyond the recommended period provide documented
14 justification and perform a timely assessment and ongoing monitoring of metabolic and
15 neurologic variables in accordance with the American Academy of Child and Adolescent
16 Psychiatry's Practice Parameter for the Use of Atypical Antipsychotic Medications in
17 Children and Adolescents.